By F. Fabio. Columbia College, South Carolina.

If the heel varus is persisting even at 6 yrs age buy generic nizagara from india erectile dysfunction treatment injection cost, Dwyer’s calcaneal osteoteotomy is advised discount nizagara 100mg erectile dysfunction pills dischem. For persisting round contour of the lateral border of the foot one of the lateral column shortening operations is performed. A supramalleolar osteotomy of tibia is indicated for persisting excessive tibial torsion. Incidence: The exact incidence in India is not worked out though the condition is not very rare. Dislocated hip has a short limb, increased creases on the inner aspect of thighs, femoral head present anteriorly , abduction of hip is restricted and telescopy positive. If the acetabular coverage is not enough, Salter’s innominate osteotomy is indicated. In a slightly older child, in addition femoral shortening derotational osteotomy may be beneficial. Introduction: Gout characterized by recurrent attacks of acute inflammatory arthritis— a red, tender, hot, swollen joint. The metatarsal-phalangeal joint at the base of the big toe is the most commonly affected (approximately 50% of cases). It is caused by elevated levels of uric acid in the blood which crystallize and are deposited in joints, tendons, and surrounding tissues. It very rarely affects pre- menopausal women & such a patient should be viewed with suspicion if a diagnosis of gout is made. Gout can present in a number of ways, although the most usual is a recurrent attack of acute inflammatory arthritis. The metatarsal- phalangeal joint at the base of the big toe is affected most often, accounting for half of cases. Other symptoms that may occur along with the joint pain include fatigue and a high fever. Long-standing elevated uric acid levels (hyperuricemia) may result in other symptomatology, including hard, painless deposits of uric acid crystals known as tophi. Elevated levels of uric acid may also lead to crystals precipitating in the kidneys, resulting in stone formation and subsequent urate nephropathy. A number of factors have been found to influence rates of gout, including age, race, and the season 127 of the year. Clinical diagnosis: Usual presentation is acute inflammatory arthritis—a red, tender, hot, swollen joint. The metatarsal-phalangeal joint at the base of the big toe is the most commonly affected (approximately 50% of cases). It is caused by elevated levels of uric acid in the blood which crystallize and are deposited in joints, tendons, and surrounding tissues. Referral criteria: For further evaluation and management of cases not responding to conventional therapy. A variety of causes—hereditary, developmental, metabolic, and mechanical—may initiate processes leading to loss of cartilage, When bone surfaces become less well protected by cartilage, bone may be exposed and damaged. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may become more lax. Case Definition: Osteoarthritis can be classified into either primary or secondary depending on whether or not there is an identifiable underlying cause. A number of studies have shown that there is a greater prevalence of the disease among siblings and especially identical twins, indicating a hereditary basis. Clinical diagnosis: The main symptom is pain, causing loss of ability and often stiffness. It commonly affects the hands, feet, spine, and the large weight bearing joints, such as the hips and knees, although in theory, any joint in the body can be affected. X Ray - Particularly standing xrays for knees in which eccentric joint space reduction is the diagnostic crieterion as compared to inflammatory where there is concentric space reduction. Referral criteria: For further evaluation and management of cases not responding to conventional therapy. Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled clinical trial. Wandel - Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis -- Wandel et al. Introduction: Osteomalacia is a generalized bone condition in which there is inadequate mineralization of the bone. Many of the effects of the disease overlap with the more common osteoporosis, but the two diseases are significantly different. There are two main causes of osteomalacia: (1) insufficient calcium absorption from the intestine because of lack of dietary calcium or a deficiency of or resistance to the action of vitamin D; and (2) Phosphate deficiency caused by increased renal losses b. Case Definition: Osteomalacia is the softening of the bones due to defective bone mineralization secondary to inadequate amounts of available phosphorus and calcium. It may show signs as diffuse body pains, muscle weakness, and fragility of the bones. In the Middle East, a high prevalence of rickets and osteomalacia has been described in Muslim women and their infants, perhaps due to increased clothing coverage of the skin. Clinical diagnosis: Osteomalacia in adults starts insidiously as aches and pains in the lumbar (lower back) region and thighs, spreading later to the arms and ribs. The pain is symmetrical, non-radiating and is accompanied by sensitivity in the involved bones. Proximal muscles are weak, and there is difficulty in climbing up stairs and getting up from a squatting position. However, those physical signs may derive from a previous osteomalacial state, since bones do not regain their original shape after they become deformed. Investigations: Serum Calcium Serum Phosphate Alkaline Phosphatase Serum urea creatinine 24 Hr urinary calcium X rays of the deformed part c. Osteomalacia due to malabsorption may require treatment by injection or daily oral dosing of significant amounts of vitamin D Standard Operating Procedure i. Referral criteria: For evaluation and management of cases not responding to conventional therapy. Introduction: Osteoporosis is a disease of bones that leads to an increased risk of fracture. The form of osteoporosis most common in women after menopause is referred to as primary type 1 or postmenopausal osteoporosis. Primary type 2 osteoporosis or senile osteoporosis occurs after age 75 and is seen in both females and males at a ratio of 2:1. Finally, secondary osteoporosis may arise at any age and affects men and women equally. Amongst the various risk factors for osteoporosis modifiable risk factors can be modified to prevent development of osteoporosis.

discount nizagara 50mg without a prescription

Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the beijing strain family buy cheap nizagara 100 mg leading causes erectile dysfunction. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus: co-epidemics in Botswana 50mg nizagara for sale erectile dysfunction groups in mi. Epidemiological analysis of tuberculosis treatment outcome as a tool for changing tuberculosis control policy in Israel. Drug- resistant pulmnonary tuberculosis in Israel, a society of immigrants: 1985-1994. Screening and management of tuberculosis in immigrants: the challenge beyond professional competence. The new National Tuberculosis Control Programme in Israel, a country of high immigration. Drug-resistant tuberculosis in Poland in 2000: second national survey and comparison with the 1997 survey. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? P was established 1948 early Notification all cases (rate) /100,000 Year of Rifampicin introduction 1970s early Estimated incidence (all cases) 5. P was established 1963 Notification all cases (rate) 10 /100,000 Year of Rifampicin introduction 1982 Estimated incidence (all cases) 10. P was established 1973 Notification all cases (rate) 47 /100,000 Year of Rifampicin introduction 1983 Estimated incidence (all cases) /100,000 Year of Isoniazid introduction 1973 Notification new sputum smear + 4439 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 34. P was established 1989 Notification all cases (rate) 16 /100,000 Year of Rifampicin introduction 1980 Estimated incidence (all cases) 29 /100,000 Year of Isoniazid introduction 1970s Notification new sputum smear + 4889 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 7. P was established 1950 Notification all cases (rate) 72 /100,000 Year of Rifampicin introduction 1985 Estimated incidence (all cases) >80 /100,000 Year of Isoniazid introduction 1970 Notification new sputum smear + 2802 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 45. P was established 1962 Notification all cases (rate) 120 /100,000 Year of Rifampicin introduction 1969 Estimated incidence (all cases) 190. P was established 1998 Notification all cases (rate) /100,000 Year of Rifampicin introduction 1972 Estimated incidence (all cases) 74. P was established 1989 Notification all cases (rate) 125 /100,000 Year of Rifampicin introduction 1990 Estimated incidence (all cases) 201 /100,000 Year of Isoniazid introduction 1965 Notification new sputum smear + 13683 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 58 /100,000 % Use of Short Course Chemotherapy Yes % Treatment Success 86 % Use of Directly Observed Therapy Yes 70. P was established 1963 Notification all cases (rate) 28 /100,000 Year of Rifampicin introduction 1970 Estimated incidence (all cases) 28. P was established 1931 Notification all cases (rate) 3 /100,000 Year of Rifampicin introduction 1971 Estimated incidence (all cases) 3. P was established 1920 Notification all cases (rate) 93 /100,000 Year of Rifampicin introduction 1972 Estimated incidence (all cases) /100,000 Year of Isoniazid introduction 1950s Notification new sputum smear + 380 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 40. P was established 1957 Notification all cases (rate) /100,000 Year of Rifampicin introduction 1970s Estimated incidence (all cases) 44. P was established (revised programme) Notification all cases (rate) 251 /100,000 Year of Rifampicin introduction 1979 Estimated incidence (all cases) 827 /100,000 Year of Isoniazid introduction 1968 Notification new sputum smear + 12393 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 135 /100,000 % Use of Short Course Chemotherapy Yes 100 % Treatment Success 58. P was established (revised programme) Notification all cases (rate) 400 /100,000 Year of Rifampicin introduction 1979 Estimated incidence (all cases) 875 /100,000 Year of Isoniazid introduction 1968 Notification new sputum smear + 15346 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 219 /100,000 % Use of Short Course Chemotherapy Yes 100 % Treatment Success 60. P was established (revised programme) Notification all cases (rate) 188 /100,000 Year of Rifampicin introduction 1979 Estimated incidence (all cases) 578 /100,000 Year of Isoniazid introduction 1968 Notification new sputum smear + 4296 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 138 /100,000 % Use of Short Course Chemotherapy Yes 100 % Treatment Success 67. P was established (revised programme) Notification all cases (rate) 423 /100,000 Year of Rifampicin introduction 1979 Estimated incidence (all cases) 530 /100,000 Year of Isoniazid introduction 1968 Notification new sputum smear + 6455 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 228 /100,000 % Use of Short Course Chemotherapy Yes 100 % Treatment Success 69. P was established (revised programme) Notification all cases (rate) 632 /100,000 Year of Rifampicin introduction 1979 Estimated incidence (all cases) 932 /100,000 Year of Isoniazid introduction 1968 Notification new sputum smear + 15264 Use of Standardized Regimens Yes Notification new sputum smear + (rate) 359 /100,000 % Use of Short Course Chemotherapy Yes 100 % Treatment Success 70. P was established 1953 Notification all cases (rate) 6 /100,000 Year of Rifampicin introduction 1971 Estimated incidence (all cases) 5. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. Migliori, Dr Giorgio Besozzi, Dr Antonio Cassone, Dr Graziella Orefici, Dr Lanfranco Fattorini, Dr Elisabetta Iona • Latvia: Dr Janis Leimans, Dr Vaira Leimane, Dr Dace Mihalovska, Dr Sven Hoffner • Malaysia: Dr Iyawoo Kuppusamy, Dr Denis Padmini, Ms Soshila Ramayah, Dr Chyoji Abe • Mexico: Dr Adalberto Santaella-Solis, Dr Susana Balandrano Campos, Dr Ana Flisser Steinbruch, Dr Reuben Granich, Dr Nancy Binkin • Morocco: Dr Salah-Eddine Ottmani, Dr Jaouad Mahjour, Dr Fadila Boulahbal, Dr Pierre Chaulet • Mozambique: Dr Alfredo MacArthur Jr. Lambregts-van Weezenbeek, Dr Nico Kalisvaart • New Caledonia: Dr Philippe Duval, Dr Fadila Boulahbal • New Zealand: Dr Maggie Brett, Dr Ross Vaughan, Dr Mary Carr, Dr Catherine Tocker • Nicaragua: Dr Luis Chacon, Dr José Ramón Cruz, Dr Adalbert Laszlo, Dr Ana Reniero • Norway: Dr Einar Heldal, Dr Nanne Brattås, Dr Per Sandven • Oman: Dr Ali Ahmed Ba Omar, Dr Salah Al- Awan, Dr Suleiman AlBusaidy, Mr Jacob George, Dr Fadila Boulahbal • Peru: Ms Lucy Vàsquez Campos, Dr Jaime Portocarrero Céliz, Dr Pedro G. Suarez, Dr Ana Reniero • Poland: Prof Zofia Zwolska, Prof Kazimierz Roszkowski, Dr Bert van Klingeren • Puerto Rico: Dr Olga Joglar, Dr Ida Onorato, Dr Eugene McCray • Republic of Korea: Dr Sang Jae Kim, Dr Gill-Han Bai • Russian Federation (Ivanovo Oblast): Prof Alexander G. Stoyunin, Dr Natalia Katulina, Dr Irina Danilova, Dr Valentina Golyshevskaya • Russian Federation (Tomsk Oblast): Dr Alex Sloutsky, Dr Alex Goldfarb, Dr Tim Healing, Dr Michael Kimerling • Sierra Leone: Dr Lars Westman, Mr Abu G. George, Dr Gisela Bretzel • Singapore: Dr Jane Yap, Dr Ian Snodgrass, Dr Chyoji Abe • Slovakia: Dr Mária Svejnochová, Dr Eva Rajecová, Prof Ladislav Chovan, Dr Marta Havelková • Slovenia: Mag Manca ëolnir-Dov‹, Dr Jurij áorli, Dr Damijan Erìen, Dr Sabine Rüsch-Gerdes • South Africa: Dr Karin Weyer • Spain (Barcelona): Dr Nuria Martin-Casabona • Sweden: Dr Gunilla Källenius, Dr Sven Hoffner, Dr Victoria Romanus • Switzerland: Dr Peter Helbling, Dr Gaby E. This project could not have succeeded without the support of national authorities and the institutions hosting each of the national and international laboratories. Mr Mark Fussell, Dr Tom Frieden, Dr Jacob Kumaresan, and Dr Paul Nunn provided useful comments. The secretarial assistance of Ms Cora Dolores and Ms Zahra Ali-Piazza is also recognized. It gives the results of the survey conducted between 1996 and 1999, three years after the first survey, with the aim at collecting worldwide information on drug resistance of Mycobacterium tuberculosis. It is a great step forward compared with the information of the first survey collect- ed from 35 geographical settings. Without their intensive and meticulous work, the survey would not have been possible. It is therefore my duty and my pleasure to recognise their work and to congratulate them. They provided the key information on previous history of drug treatment that permits to classify the patients as new cases if they had no previous history of treatment; and as previ- ously treated cases if they had previous history of treatment, in other words if they have failed to be cured after one or several episodes of therapy. The distinction is of crucial im- portance because it is well known for the last fifty years that failure to be cured is often as- sociated with, if not caused by the selection of drug resistant mutants, high prevalence of drug resistance being the main characteristic of previously treated patients. Failing to iden- tify those previously treated patients among all patients would result in confused informa- tion on drug resistance in a given setting. The collection of reliable clinical data is therefore essential for surveys on drug resistance. In addition, it is intimately linked with the sam- pling of the patients to be included in the survey. To prevent, or at least limit, the possible bias in sampling, two suggestions might be made: first, to collect prospectively and not ret- rospectively the clinical information; second, to enrol consecutive patients and not to enrol separately new cases and previously treated cases. Doing so would provide the proportion of previously treated patients among the tuberculosis patients, an essential indicator for the quality of the control programme in a given population. In the present report, the read- ers might be amazed by the decision to abandon the terms "primary" and "acquired" drug resistance.

buy nizagara without prescription

Actual splitting of fructose 1 order generic nizagara pills erectile dysfunction treatment in kuwait,6 diphosphate Fructose 1 order nizagara uk erectile dysfunction symptoms causes and treatments,6 diphosphate is split by the enzyme aldolase into two molecules of triose phosphates, an aldotriose-glyceraldehyde 3-phosphate and one ketotriose - dihydroxy acetone phosphate. Reactions of this type in which an aldehyde group is oxidised to an acid are accompanied by liberation of large amounts of potentially useful energy. Oxidation of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate Glycolysis proceeds by the oxidation of glyceraldehyde 3-phosphate to form 1,3-bisphosphoglycerate. Conversion of 1,3-bisphosphoglycerate to 3-phosphoglycerate The reaction is catalyzed by the enzyme phosphoglycerate kinase. Conversion of 2-phosphoglycerate to phosphoenol pyruvate The reaction is catalyzed by the enzyme enolase, the enzyme requires the presence of either Mg2+ or Mn2+ ions for activity. Conversion of phosphoenol pyruvate to pyruvate Phosphoenol pyruvate is converted to pyruvate, the reaction is catalysed by the enzyme pyruvate kinase. Under aerobic conditions, pyruvate is oxidatively decarboxylated to acetyl coenzyme A (active acetate) before entering the citric acid cycle. Formation of citrate The frst reaction of the cycle is the condensation of acetyl CoA with oxaloacetate to form citrate, catalyzed by citrate synthase. Formation of isocitrate via cis aconitate The enzyme aconitase catalyzes the reversible transformation of citrate to isocitrate, through the intermediary formation of cis aconitate. Conversion of succinyl CoA to succinate The product of the preceding step, succinyl CoA is converted to succinate to continue the cycle. Hydration of fumarate to malate The reversible hydration of fumarate to malate is catalyzed by fumarase. As one molecule of glucose gives rise to two molecules of pyruvate by glycolysis, intermediates of citric acid cycle also result as two molecules. The frst reaction of the pentose phosphate pathway is the dehydrogenation of glucose 6-phosphate by glucose 6-phosphate dehydrogenase to form 6-phosphoglucono d-lactone. Glycogenesis is a very essential process since the excess of glucose is converted and stored up as glycogen which could be utilised at the time of requirement. In the absence of this process the tissues are exposed to excess of glucose immediately after a meal and they are starved of it at other times. Step 1 The frst step in the breakdown of glycogen is catalyzed by two enzymes which act independently. The frst enzyme, namely glycogen phosphorylase with inorganic phosphate catalyses the cleavage of a terminal a 1-4 bond of glycogen to produce glycogen with one molecule less and a molecule of glucose 1-phosphate. This is carried out by another enzyme called the debranching enzyme (a 1-6 glucosidase) which hydrolyses these bonds and thus make more a 1-4 linkage accessible to the action of glycogen phosphorylase. The combined action of glycogen phosphorylase and the debranching enzyme converts glycogen to glucose 1-phosphate. Glucose 6-phosphatase removes phosphate group from glucose 6-phosphate enabling the free glucose to diffuse from the cell into the extra cellular spaces including blood. It usually occurs when the carbohydrate in the diet is insuffcient to meet the demand in the body, with the intake of protein rich diet and at the time of starvation, when tissue proteins are broken down to amino acids. In glycolysis, glucose is converted to pyruvate and in gluconeogenesis pyruvate is converted to glucose. Fructose 6-phosphate is formed from fructose 1,6-diphosphate by hydrolysis and the enzyme fructose 1,6-diphosphatase catalyses this reaction. Most of the glucogenic amino acids are converted to the intermediates of citric acid cycle either by transamination or deamination. Further metabolism of glycerol does not take place in the adipose tissue because of the lack of glycerol kinase necessary to phosphorylate it. Instead, glycerol passes to the liver where it is phosphorylated to glycerol 3-phosphate by the enzyme glycerol kinase. Hence, glycogen stored up in the muscle is converted into lactic acid by glycogenolysis followed by anaerobic glycolysis and thus lactate gets accumulated in the muscle. Muscle tissue lacks the enzyme glucose 6-phosphatase hence it is incapable of synthesizing glucose from lactic acid and the conversion take place only in the liver. In the liver lactate is oxidised to pyruvate which undergoes the process of gluconeogenesis resulting in the resynthesis of glucose. The glycogen may be once again converted to glucose (glycogenolysis) and may be recycled to the muscle through the blood. The process of gluconeogenesis completes the cycle by converting glucose once again to muscle glycogen. So the word diabetes milletus refers to chronic excretion of large volume of urine containing glucose. Diabetes mellitus, caused by a defciency in the secretion or action of insulin, is a relatively common disease. Diabetes mellitus is really a group of diseases in which the regulatory activity of insulin is defective. Type one requires insulin therapy and careful, life long control of the balance between glucose intake and insulin dose. Decreased permeability of the cell membrane for glucose resulting in the accumulation of glucose in the blood. The diabetic has voracious appetite, but inspite of over eating, they lose weight and become lean and emaciated. As glucose is not enough for energy production, increased mobilisation of fat from adipose tissue occurs. But the metabolism of fat is incomplete resulting in the production of large amounts of the intermediary products of fat metabolism namely ketone bodies (eg. Biochemical measurements on the blood and urine are essential in the diagnosis and treatment of diabetes, which causes profound changes in metabolism. The blood glucose concentration is measured before the test dose and at 30 min intervals for several hours thereafter. A normal individual assimilates the glucose readily, the blood glucose rising to no more than about 80 to 120 mg/100 ml; little or no glucose appears in the urine. Diabetic individuals assimilate the test dose of glucose poorly; their blood glucose level far exceeds the kidney threshold (about 180 mg/100ml), causing glucose to appear in their urine. Which one of the following enzyme is involved in substrate level phosphorylation i) citrate synthase ii) isocitrate dehydrogenase iii) succinyl CoA synthetase iv) fumarase f. The bonding is catalysed by the enzyme peptidyl transferase which is present in 50s ribosomal subunit. A peptide bond is formed between the third amino acid of site-A and the second amino acid of the dipeptide present in the P-site. The elongation of polypeptide chain is brought about by a number of protein factors called elongation factors. The reactions of deamination and transamination bring about the formation of keto acids which can undergo a further series of changes. Inter- conversion between keto acids and amino acids results in the synthesis of many nutritionally non essential amino acids. During protein synthesis the amino acids are absorbed from the blood, as the liver does not store them.

generic 50 mg nizagara amex

purchase generic nizagara pills

Work stress buy generic nizagara 25 mg online impotence tumblr, substance use nizagara 50 mg sale impotence treatment natural, and depression among young adult workers: An examination of main and moderator effect model. Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: A controlled study. Behavioral and emotional self-control: Relations to substance use in samples of middle and high school students. Depressive symptoms and cigarette smoking among middle adolescents: Prospective associations and intrapersonal and interpersonal influences. Adolescent temperament and lifetime psychiatric and substance abuse disorders assessed in young adulthood. Motivational enhancement therapy to improve treatment utilization and outcome in pregnant substance users. Behavioral couples therapy for female substance-abusing patients: Effects on substance use and relationship adjustment. Treating adolescents with substance use disorders: An overview of practice issues and treatment outcome. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. Service utilization during and after outpatient treatment for comorbid substance use disorder and depression. The multidimensional structure of internal barriers to substance abuse treatment and its invariance across gender, ethnicity, and age. Encouraging physicians to screen for and intervene in substance use disorders: Obstacles and strategies for change. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. Mental health professionals with a specialty in anxiety disorders: Knowledge, training, and perceived competence in smoking cessation practices. Currently, drug use and abuse is a very serious social and public health problem that generates great social concern. This is due to the widespread drug consumption in many sectors of the population, the decline in the age of usage initiation and the severity of the individual and community consequences of the phenomenon on the three levels considered in the current concept of health: physical, psychological and social. If a few years ago, speaking of the drug problem usually alluded to illegal drugs such as heroin, currently the concern has focused on the consumption of legal drugs such as alcohol and tobacco, which are considered the gateway to the consumption of other substances. Alcohol and tobacco are also considered the gateway to the use of substances whose consumption is increasing, cannabis and cocaine. Nevertheless, preventive and therapeutic action, given the continuous change and complexity of the phenomenon, is still insufficient. We review aspects such as the definition of drugs and addictive behavior, consumption patterns and the current status of the problem. Also presented are the criteria used to determine whether consumption or abuse of a substance is taking place. Finally, we review the main individual risk factors that favor substance consumption and integrate them into a comprehensive model. To understand the magnitude of the phenomenon it is necessary to know the basic physiological correlates of drug consumption. In this first unit general concepts on the pharmacodynamics and pharmacokinetics of drug consumption are addressed. The characteristics of the main psychoactive substances and their psychoactive effects and mechanisms are also presented. Others are the result of chemical processes carried out using natural products, like what occurs with alcoholic beverages, which are obtained from the fermentation or distillation of grain or fruit juice. There has also been a differentiation between soft and hard drugs, although currently that distinction is rarely used because of its scant utility and the fact that it can give rise to the erroneous interpretation that so-called soft drugs are not quite detrimental to health. The first group includes alcohol, opiates and psychotropic drugs such as hypnotics, anxiolytics and antipsychotics. In the third group, consisting of psychedelic drugs, are hallucinogens, cannabis, synthetic drugs and solvents (e. Central Nervous System Depressants a) Alcohol b) Hypnotics: Barbiturates and non-barbiturates c) Anxiolytics: diazepam d) Narcotic analgesics: i. Drug consumption becomes abusive at the appearance of dependence, which is defined as the set of physiological, behavioral and cognitive manifestations in which the use of a drug is a priority for the individual. This term is usually linked to tolerance, or the need to consume more of a substance to achieve the effects of previous consumption. It is a cluster of symptoms that affect an individual who is suddenly deprived of any toxin or drug on which he/she is physically dependent and which previously had been consumed on a regular basis. The quantity of symptoms, as well as their intensity and duration will depend on the type of drug, the length of time the person has consumed the substance and his/her physical and psychological state at the time of withdrawal. Physical dependence is a state of adaptation of the organism to the presence of the drug and is manifested by the appearance of intense physical discomfort (tremors, chills, insomnia, vomiting, pain in the muscles and bones, etc. This same physical discomfort occurs when the substance´s action on the organism is influenced by drugs designed to block its effects. Psychological dependence refers to the situation in which a person feels an emotional need and urge to consume a drug on a regular basis in order to feel good, be satisfied (obtain pleasure or avoid discomfort) although he/she does not need the substance physiologically. There are the so-called non-toxic addictions which involve dependency behavior with an evident syndrome of psychological withdrawal. There is, for example, addiction to gambling or pathological gambling and others such as technological addictions (internet, mobile, and video games), addiction to shopping, exercise or sex. These addictive behaviors share, if not all, some of the characteristics mentioned so far, with the peculiarity that there is not a mediating substance that produces physical changes in the subject. Effects of Drugs 4 José Pedro Espada and Daniel Lloret Irles As already mentioned, drugs act on the central nervous system (i. The physiological correlates and effects vary according to each substance; there are specific mechanisms that involve precise receptors for each substance type. When a substance enters the body it first affects the neuronal receptors, which are structures located within a neuron or in its membrane and are characterized by selective binding to a substance and the physiological effect that accompanies the union. The presence of a drug in the body affects the presynapse, altering the production/ release of neurotransmitters. During the next step, the drug affects the synapses, by increasing the presence of neurotransmitters in the synaptic space. The activity of the drug in the body over a period of time comprises the processes of absorption, distribution, localization in tissues, biotransformation and excretion. Central Nervous System Depressants Alcohol The two main types of alcohol based on their chemical composition are: methyl alcohol (methanol), which is the simplest of the alcohols and is used as a solvent, antifreeze and in industrial applications; and ethyl alcohol (ethanol), which is what alcoholic beverages contain.

9 of 10 - Review by F. Fabio
Votes: 201 votes
Total customer reviews: 201

Get Cloud PHP Hosting on CatN